AMNEAL PHARMACEUTICALS, INC. Comprehensive Income
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Comprehensive Income of $69.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was $69.15M, a 544.67% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was $60.83M.
- AMNEAL PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was $30.23M.
- AMNEAL PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$6.08M.
- AMNEAL PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was $26.84M.
- AMNEAL PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$150.05M.
- AMNEAL PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$127.04M.
- AMNEAL PHARMACEUTICALS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$95.11M, a 447.87% decline from fiscal 2021.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $69.15M 10-Q · filed 2026-08-06 | $129.98M 10-Q · filed 2026-08-06 | $160.21M derived: sum of 3 quarters · filed 2026-08-06 | $154.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $60.83M 10-Q · filed 2026-05-07 | $91.06M derived: sum of 2 quarters · filed 2026-05-07 | $84.98M derived: sum of 3 quarters · filed 2026-05-07 | $95.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $30.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $24.15M derived: sum of 2 quarters · filed 2026-02-27 | $34.87M derived: sum of 3 quarters · filed 2026-08-06 | $26.84M 10-K · filed 2026-02-27 |
| 2025-09-30 | -$6.08M 10-Q · filed 2025-11-06 | $4.64M derived: sum of 2 quarters · filed 2026-08-06 | -$3.39M 10-Q · filed 2025-11-06 | -$26.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $10.73M 10-Q · filed 2026-08-06 | $2.69M 10-Q · filed 2026-08-06 | -$20.12M derived: sum of 3 quarters · filed 2026-08-06 | -$63.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$8.04M 10-Q · filed 2026-05-07 | -$30.84M derived: sum of 2 quarters · filed 2026-05-07 | -$74.35M derived: sum of 3 quarters · filed 2026-05-07 | -$75.08M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$22.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$66.31M derived: sum of 2 quarters · filed 2026-02-27 | -$67.04M derived: sum of 3 quarters · filed 2026-02-27 | -$150.05M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$43.50M 10-Q · filed 2025-11-06 | -$44.23M derived: sum of 2 quarters · filed 2025-11-06 | -$127.24M 10-Q · filed 2025-11-06 | -$262.79M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | -$731.00K 10-Q · filed 2025-08-07 | -$83.74M 10-Q · filed 2025-08-07 | -$219.29M derived: sum of 3 quarters · filed 2026-02-27 | -$213.82M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | -$83.00M 10-Q · filed 2025-05-07 | -$218.56M derived: sum of 2 quarters · filed 2026-02-27 | -$213.09M derived: sum of 3 quarters · filed 2026-02-27 | -$196.87M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | -$135.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$130.09M derived: sum of 2 quarters · filed 2026-02-27 | -$113.86M derived: sum of 3 quarters · filed 2026-02-27 | -$127.04M 10-K · filed 2026-02-27 |
| 2023-09-30 | $5.46M 10-Q · filed 2024-11-12 | $21.69M derived: sum of 2 quarters · filed 2024-11-12 | $8.51M 10-Q · filed 2024-11-12 | $1.57M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $16.23M 10-Q · filed 2024-08-09 | $3.05M 10-Q · filed 2024-08-09 | -$3.89M derived: sum of 3 quarters · filed 2025-02-28 | $5.09M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | -$13.18M 10-Q · filed 2024-05-08 | -$20.11M derived: sum of 2 quarters · filed 2025-02-28 | -$11.13M derived: sum of 3 quarters · filed 2025-02-28 | -$130.72M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | -$6.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $2.05M derived: sum of 2 quarters · filed 2025-02-28 | -$117.54M derived: sum of 3 quarters · filed 2025-02-28 | -$95.11M 10-K · filed 2025-02-28 |
| 2022-09-30 | $8.98M 10-Q · filed 2023-11-09 | -$110.61M derived: sum of 2 quarters · filed 2023-11-09 | -$88.17M 10-Q · filed 2023-11-09 | -$86.14M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | -$119.59M 10-Q · filed 2023-08-08 | -$97.16M 10-Q · filed 2023-08-08 | -$95.13M derived: sum of 3 quarters · filed 2024-03-14 | -$98.60M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $22.43M 10-Q · filed 2023-05-09 | $24.47M derived: sum of 2 quarters · filed 2024-03-14 | $21.00M derived: sum of 3 quarters · filed 2024-03-14 | $35.97M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$1.44M derived: sum of 2 quarters · filed 2024-03-14 | $13.53M derived: sum of 3 quarters · filed 2024-03-14 | $27.34M 10-K · filed 2024-03-14 |
| 2021-09-30 | -$3.47M 10-Q · filed 2022-11-07 | $11.50M derived: sum of 2 quarters · filed 2022-11-07 | $25.31M 10-Q · filed 2022-11-07 | $22.27M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $14.97M 10-Q · filed 2022-08-08 | $28.78M 10-Q · filed 2022-08-08 | $25.74M derived: sum of 3 quarters · filed 2023-03-03 | $15.17M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $13.81M 10-Q · filed 2022-05-06 | $10.77M derived: sum of 2 quarters · filed 2023-03-03 | $202.00K derived: sum of 3 quarters · filed 2023-03-03 | -$18.06M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | -$3.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | -$13.61M derived: sum of 2 quarters · filed 2023-03-03 | -$31.87M derived: sum of 3 quarters · filed 2023-03-03 | $49.86M 10-K · filed 2023-03-03 |
| 2020-09-30 | -$10.57M 10-Q · filed 2021-11-08 | -$28.84M derived: sum of 2 quarters · filed 2021-11-08 | $52.89M 10-Q · filed 2021-11-08 | $26.04M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$18.27M 10-Q · filed 2021-08-09 | $63.46M 10-Q · filed 2021-08-09 | $36.61M derived: sum of 3 quarters · filed 2022-03-01 | -$226.21M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $81.73M 10-Q · filed 2021-05-07 | $54.88M derived: sum of 2 quarters · filed 2022-03-01 | -$207.94M derived: sum of 3 quarters · filed 2022-03-01 | -$227.49M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$26.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$289.68M derived: sum of 2 quarters · filed 2022-03-01 | -$309.22M derived: sum of 3 quarters · filed 2022-03-01 | -$353.42M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$262.82M 10-Q · filed 2020-11-06 | -$282.37M derived: sum of 2 quarters · filed 2020-11-06 | -$326.57M 10-Q · filed 2020-11-06 | -$333.20M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$19.55M 10-Q · filed 2020-08-06 | -$63.75M 10-Q · filed 2020-08-06 | -$70.38M derived: sum of 3 quarters · filed 2021-03-01 | -$66.81M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | -$44.20M 10-Q · filed 2020-05-11 | -$50.83M derived: sum of 2 quarters · filed 2021-03-01 | -$47.26M derived: sum of 3 quarters · filed 2021-03-01 | -$67.54M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$6.63M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$3.06M derived: sum of 2 quarters · filed 2021-03-01 | -$23.34M derived: sum of 3 quarters · filed 2021-03-01 | -$23.34M 10-K · filed 2021-03-01 |
| 2018-09-30 | $3.57M 10-Q · filed 2019-11-07 | -$16.71M derived: sum of 2 quarters · filed 2019-11-07 | -$16.71M 10-Q · filed 2019-11-07 | -$16.71M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | -$20.27M 10-Q · filed 2019-08-05 | -$20.27M 10-Q · filed 2019-08-05 | -$20.27M derived: sum of 3 quarters · filed 2020-03-02 | -$20.27M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 derived: sum of 3 quarters · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $0.00 10-Q · filed 2018-08-09 | $0.00 10-Q · filed 2018-08-09 | ||
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |